Pancreatic islet transplantation has become an established approach to β-cell replacement
therapy for the treatment of insulin-deficient diabetes. Recent progress in techniques for islet …

Diabetes mellitus is a metabolic disorder that affects more than 460 million people
worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas …

We report the 1-year results from one patient as the preliminary analysis of a first-in-human
phase I clinical trial (ChiCTR2300072200) assessing the feasibility of autologous …

Hypoglycemia is a common complication in patients with diabetes, mainly in those treated
with insulin, sulfonylurea, or glinide. Impairments in counterregulatory responses and …

The main goal of treatment for type 1 diabetes is to control glycaemia with insulin therapy to
reduce disease complications. For some patients, technological approaches to insulin …

Technological advancements in blood glucose monitoring and therapeutic insulin
administration have improved the quality of life for people with type 1 diabetes. However …

Since its introduction more than twenty years ago, intraportal allogeneic cadaveric islet
transplantation has been shown to be a promising therapy for patients with Type I Diabetes …

For the past century, insulin injections have saved millions of lives, but glycemic instability is
still a persistent challenge for people with diabetes, leading to tremendous morbidity and …

Hypoglycaemia is a low blood glucose concentration and an indicator of diabetes mellitus,
and are associated with physical and psychological morbidity. It is a common, potentially …

Allogeneic islet transplant offers a minimally invasive option for β cell replacement in the
treatment of type 1 diabetes (T1D). The CIT consortium trial of purified human pancreatic …